Harpreet Singh

Follow us on social media
Healthcare
On site

Harpreet Singh

CEO of Immatics N.V.

Harpreet Singh is Chief Executive Officer and Co-Founder of Immatics, a NASDAQ-listed public company engaged in the development of novel immunotherapies designed to have a meaningful impact on the lives of cancer patients. The company is building a clinical pipeline of T cell Receptor (TCR) therapeutics including autologous and allogeneic cell therapies and bispecifics. The company went public at NASDAQ in 2020 and has entered partnerships with multiple leading pharma players. Harpreet is the inventor/author on numerous granted patents and scientific papers. A scholar of Hans-Georg Rammensee, he completed his academic studies by gaining a Ph.D. in immunology at the University of Tuebingen, Germany.
Follow us on social media

Agenda

Wednesday, July 10 | 
15:00
 — 15:30
Developing living drugs against cancer: TCR-T cell therapies
Sign up for the Curious Future Insight Newsletter

Future Insight e.V. is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose vis e-mail, please fill out the fields below:

By clicking submit below, you consent to allow Future Insight e.V. to store and process the personal information submitted above to provide you the content requested.

Thank you for subscribing!

Cookies

We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operation of the app and the website, as well as other cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for the display of personalized content. You are free to decide in the Cookie Settings which categories you would like to permit. Please note that depending on what you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Statement.